Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits

Completed

• Conditions: Recurrence of HCC After LDLT

• Registration Number: NCT01937286
• Lead Sponsor: Ain Shams University

Brief Summary

Within community with high incidence of HCC, stretching the limits could be justified based on tumor characters and its biological behavior

Detailed Description

590 Egyptian patients underwent LDLT; of them, 172 (32%) patients were transplanted for HCC. Twenty six cases (15.1%) were excluded due to early postoperative mortality (n=22) or due to non HCC related mortality (n=4). One hundred forty six patients were retrospectively reviewed to determine prognostic factors for recurrence.

Study Timeline

• Study Start: 2002-01
• Primary Completion: 2011-12
• Study Completion: 2012-04
• Status Verified: 2013-09
• Study First Submitted: 2013-09-04
• Study First Submitted QC: 2013-09-04
• Last Update Submitted: 2013-09-04
• Study First Posted: 2013-09-09
• Last Update Posted: 2013-09-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 590

Inclusion Criteria

• Egyptien Patients with HCC
• Patients within Milan Criteria
• Patients beyond Milan criteria are selected on a case by case basis until 2005. From 2005 , patients beyond Milan criteria are subjected to down staging protocol and then reassessed (pre transplantation local ablative therapy either with RFA or TACE according to the size and the site of the lesion and we wait for 12 weeks after ablation ,only those with well ablated lesions, decreased AFP and no denovo lesions were transplanted).

Exclusion Criteria

• • Evidence of macro vascular invasion by CT portography and/or US duplex.

  • Metastatic HCC
  • General contraindications for LT (ongoing sepsis, other major co morbidities,...).
  • Early postoperative mortality (first1 month).
  • Post transplant mortality during the period of follow up due to any cause other than recurrent HCC (e.g. sepsis, rejection, cardiological or cerebrovascular complications...)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Recurrence of Hepatocellular carcinoma after LDLT	at least 6 months

Trial Locations

Locations (1)

Ain Shams Center For Organ Transplantation (ASCOT),Ain Shams university; 🇪🇬 Cairo,, Egypt